| HOME >> MEDICINE >> TECHNOLOGY |
CSL654 (rFIX-albumin fusion; CSL Behring)
BIIB 029 (rFIXFc; Biogen Idec)
NN7999 (rFIX, glycoPEGylated; Novo Nordisk)
Clinical and commercial attractiveness for key hemophilia B pipeline products
Bibliography
Journal articles and online sources
Appendix
Methodology
Datamonitor drug assessment for clinical and commercial attractiveness
TABLES
Table: Clinical pipeline key drugs for hemophilia A and B, November 2012
Table: Kogenate FS (recombinant Factor VIII; Bayer) – drug profile, 2012
Table: Kogenate FS (recombinant Factor VIII; Bayer) – drug profile, 2012
Table: Kogenate FS (rFVIII; Bayer) and BeneFIX (rFIX; Pfizer) vs the target product profile in previously treated patients, 2012
Table: Key events in the clinical development of NN7008 (turoctocog alfa; Novo Nordisk), 2012
Table: Key events in the clinical development of BIIB 031 (rFVIIIFc; Biogen Idec), 2012
Table: Key events for the clinical development of NN7088 (Novo Nordisk), 2012
Table: Key events for the clinical development of BAY-94-9027 (Bayer), 2012
Table: Key events for the clinical development of BAX 326 (Baxter), 2012
Table: Key events for the clinical development of CSL654 (CSL Behring), 2012
Table: Key events for the clinical development of BIIB 029 (rFIXFc; Biogen Idec), 2012
Table: Key events for the clinical development of NN7999 (Novo Nordisk), 2012
FIGURES
Figure: Clinical and commercial attractiveness for key hemophilia A pipeline drugs vs comparator Kogenate FS (rFVIII; Bayer), 2012
Figure: Breakdown of clinical and commercial attractiveness attributes for key hemophilia A pipeline drugs, 2012
Figure: Launch timeline for key hemophilia A pipeline drugs, 2012
Figure: Clinical and commercial attractiveness for key hemophilia B pipeline drugs vs comparator B
'/>"/>
| SOURCE Reportlinker Copyright©2012 PR Newswire. All rights reserved |